Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy

Diabetes, Obesity and Metabolism

Volumn 8, Issue 2, 2006, Pages 156-163

  Garber, A ^a   Klein, E ^b   Bruce, S ^c   Sankoh, S ^c   Mohideen, Pharis ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b West Olympia Internal Medicine Associates   (United States)

^c BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

Combination therapy; Glibenclamide; Glyburide; Metformin; Rosiglitazone; Type 2 diabetes

Indexed keywords

GLIBENCLAMIDE; HEMOGLOBIN A1C; METFORMIN; PLACEBO; ROSIGLITAZONE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BONE PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIARRHEA; DIET RESTRICTION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PARANASAL SINUS DISEASE; RANDOMIZED CONTROLLED TRIAL; TABLET FORMULATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

EID: 33645996998     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2005.00570.x     Document Type: Article

References (13)

1. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281-303.
2. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2002; 25: 213-229.
3. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000; 321: 405-412.
4. Stumvoll M, Nurjhan N, Perriello G et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 550-554.
5. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991; 73: 1294-1301.
6. Johnson AB, Webster JM, Sum CF et al. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. Metabolism 1993; 42: 1217-1222.
7. Garber AJ, Bruce S, Fiedorek FT. Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: An open-label extension study. Clin Ther 2002; 24: 1401-1413.
8. Fonseca V, Biswas N, Salzman A. Once-daily rosiglitazone (RSG) in combination with metformin (MET) effectively reduces hyperglycaemia in patients with type 2 diabetes [abstract] Diabetes 1999; 48 (Suppl. 1): A100.
9. Einhorn D, Rendell M, Rosenzweig J et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther 2000; 22: 1395-1409.
10. Marre M, Howlett H, Lehert P, Allavoine T. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in type 2 diabetic patients inadequately controlled on metformin. Diabet Med 2002; 19: 673 - 680.
11. Morris AD, Brennan GM, MacDonald TM, Donnan PT. Population-based adherence to prescribed medication in type 2 diabetes: A cause for concern [abstract]. Diabetes 2000 49 SUPPL.1 A76
12. Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycaemic drug regimens: Evaluation of a Medicaid patient population with type 2 diabetes mellitus. Clin Ther 2001; 23: 1311-1320.
13. Melikian C, White TJ, Vanderplas A et al. Adherence to oral antidiabetic therapy in a managed care organization: A comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002; 24: 460-467.